Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com Renu, ketolide antibiotic, kills and causes severe liver injury. Free legal consultation at Monheit.com
Renu, ketolide antibiotic, kills and causes severe liver injury. Contact a birth control injury lawyer Renu, ketolide antibiotic, kills and causes severe liver injury. Contact a birth control injury lawyer Renu, ketolide antibiotic, kills and causes severe liver injury. Contact a birth control injury lawyer Renu, ketolide antibiotic, kills and causes severe liver injury. Contact a birth control injury lawyer Renu, ketolide antibiotic, kills and causes severe liver injury. Contact a birth control injury lawyer

Bausch Lomb class action for Bausch and Lomb contact lens solution

Renu, ketolide antibiotic, kills and causes severe liver injury. Contact a birth control injury lawyer
Renu, ketolide antibiotic, kills and causes severe liver injury. Contact a birth control injury lawyer
 
Renu, ketolide antibiotic, kills and causes severe liver injury. Contact a birth control injury lawyer

Renu, ketolide antibiotic, kills and causes severe liver injury. Contact a birth control injury lawyer

ReNu with MoistureLoc linked with Fungal Keratitis
MoistureLoc / contact lens solution /corneal transplant

Contact a ReNu Lawyer Personal injury lawsuit / Bausch & Lomb / may cause blindness
Free inquiry form


ReNu Timeline Crisis
Bausch & Lomb was aware of the severe problems for 5 months before pulling ReNu off the market
www.monheit.com/timeline.asp

What is fungal keratitis?
What is the cause? Do I need a corneal transplant?
Do you have a ReNu lawsuit?

What is the problem that ReNu lawyers may help you pursue?
Bausch & Lomb negligence / severe eye infection
www.monheit.com/problem.asp

Who should your ReNu with MoistureLoc lawyers hold responsible?
Bausch & Lomb
www.monheit.com/responsible.asp

What can you expect your ReNu lawyer to do?
File a ReNu lawsuit against Bausch & Lomb
www.monheit.com/lawyer.asp

FAQs about ReNu
How much does a ReNu lawyer cost? How do I report ReNu adverse reactions? What are the symptoms of fungal keratitis?


 

Web Resources
Breaking News

Renu, ketolide antibiotic, kills and causes severe liver injury. Contact a birth control injury lawyer

ReNu Crisis Timeline

May 17, 2006
FDA finds Bausch and Lomb didn't follow the rules. FDA says 35 cases were not reported properly. Bausch & Lomb denies the allegations and said it communicated promptly and directly with the FDA regarding reports the company received about fusarium infections. On Tuesday, the FDA released the findings of an inspection team that was at the Greenville plant from March 22 until May 15. In a report, the team faulted Bausch & Lomb in 20 procedural areas. Inspectors said Bausch & Lomb failed to:

  • Do a complete design plan for the ReNu with MoistureLoc product.

  • Follow procedures to prevent contamination of equipment and product.

  • Properly define and document procedures for controlling environmental conditions.

  • Implement procedures to control storage of product in storage areas and stock rooms.

  • Conduct quality control audits.

  • Implement procedures to prevent problems during handling of product.

  • Ensure appropriate design, construction, placement, and installation of manufacturing equipment.

  • Properly document maintenance activities.

Still, the FDA said that while the team's observations at the plant may indicate deviations from current good manufacturing practice, they do not necessarily support a connection between ReNu with MoistureLoc and the fungal infections.
 

May 15, 2006
Bausch Lomb is permanently removing its Greenville-made ReNu with MoistureLoc Baush and Lomb contact lens solution from the worldwide market after concluding the product's formula may increase the risk of fungal eye infections in certain unusual circumstances. Problems with the solution were reported in the United States, Singapore, Hong Kong, and Malaysia -- all markets served by the Greenville plant. The U.S. Food and Drug Administration dispatched a team of investigators to the plant March 22, and on April 10, Bausch Lomb said it had stopped shipments of ReNu with MoistureLoc from the plant. The company and the FDA said they believe they've solved the mystery and that it lies in the chemical properties of ReNu with MoistureLoc in the manufacturing process at the Greenville plant. Exhaustive testing revealed that ReNu with MoistureLoc, under certain conditions, such as if the bottle cap is left open, allows a polymer film to form, and the Fusarium fungus, found just about everywhere, can survive on the film, insulated from alexidine, the disinfectant in ReNu with MoistureLoc. The fungal infections appear to be related to the design of this particular solution and don't stem from a problem with the manufacturing and the way in which the product leaves the facility.

April 20, 2006
Bausch Lomb class action lawsuits likely in multiple states. In Miami, an attorney is seeking class action status for a lawsuit against Bausch & Lomb for ReNu eye infections. The lawsuit alleges that plaintiffs have suffered painful eye fungus injections. These infections permanently scarred the cornea of the Bausch Lomb class action plaintiff, a woman who used its contact lens solution. The lawsuit follows a similar Bausch & Lomb class action suit filed in New York, that also alleges the company failed to remove the fungus from the Renu with MoistureLoc eye solution and/or caused the fungus to grow in the manufacturing process.

April 15, 2006
The company asks retail stores to take ReNu with MoistureLoc Bausch and Lomb contact lens solution made in the Greenville plant off the shelves temporarily but did not request that the solution be returned to the company. CEO Ron Zarrella said neither the company nor the FDA had discovered contamination at the plant after nearly three weeks of testing. The company's request that retailer pull its product did not apply to other Bausch & Lomb products or ReNu with MoistureLoc made outside the United States. The request came as several U.S. retailers led by Wal-Mart., Walgreen, and CVS Corp., were pulling the ReNu Bausch and Lomb contact lens solution with MoistureLoc solution off their shelves on their own.

The company stopped shipments of MoistureLoc in the United States when the CDC said it was scrutinizing 109 reports of fungal keratitis infections in patients in 17 states over the past 10 months.

April 12, 2006
Bausch & Lomb said that neither the company nor any of the five federal inspectors had found any evidence that contact lens solution made at its Greenville plant is connected to eye fungus infections after nearly three weeks of testing. The company also doesn't have any plans to furlough or lay off any of the approximately 450 workers at the Pelham Road facility, even though it halted shipments of solution made there. CEO Ron Zarrella said that tests have been conducted on samples of solution made at the plant, solution from store shelves, and solution used by victims who became infected and none have revealed evidence of the fungus. He said test results of swabs taken in non sterile areas of the plant aren't back from labs, but it won't be surprising if they are positive because the Fusariam fungus is found just about everywhere. Zarrella told analysts the company is ramping up production of another contact lens solution now that some retailers are pulling ReNu with MoistureLoc from their shelves but it wasn't immediately clear how that might affect the Greenville plant.

April 12, 2006
Singapore: 36 more cases of fusarium keratitis reported since the last update in late February (then 39 cases). In total, 75 cases of fungal corneal infection with a history of contact lens use have been reported.

April 10, 2006
Bausch & Lomb stopped shipping product to U.S. stores but said stores could continue to sell existing product until supplies ran out. "There's no indication there is a formula problem here," CEO Zarrella said.

March 31, 2006
Bausch and Lomb is collaborating in a surveillance program and scientific investigation to track and investigate the incidence of the infection with health authorities and leading experts around the world including the United States.

March 22, 2006
FDA begins inspection of Bausch & Lomb, Greenville, S.C. plant.

March 18, 2006
Eight victims required corneal transplants to avert blindness. Only 30 cases investigated thus far. Of those 30 cases, 28 wore soft contacts and all but two used ReNu products. Five of the 26 who used ReNu also used other solutions.

March 8, 2006
A New Jersey ophthalmologist reports three cases of rare fungal infection, fusarium keratitis to the CDC within the last three months. The U.S. investigation begins.

February 20, 2006
Bausch Lomb voluntarily suspends sales in Singapore, Malaysia, and Hong Kong after 29 cases of fungal keratitis are found in Asia since November 2005.

December 2005
Bausch & Lomb mentions but downplays the Hong Kong incident to the FDA.

November 2005
Hong Kong health officials tell Bausch & Lomb about the noted increase in hospital admissions due to contact-lens-related keratitis from June to September 2005.

June 15, 2005
First reported fusarium case reported in the United States
 


 

Why did Bausch & Lomb take so long to warn the public about possible ReNu problems?

Do you need to participate in the Bausch Lomb Class Action?

 


PERSONAL INFORMATION

Title:
First Name: *
Last Name: *
E-mail Address: *
Address:
City:
State:
Zipcode:
Phone: * () - ext.


CONTACT LENS INFORMATION

How long have you worn contact lenses?
How long have you been using ReNu with MoistureLoc contact lens solution?
What were the dates of use?
Start Date Using
End Date Using


EYE INJURY INFORMATION


Have you developed:
Fungal eye infection
Bacterial eye infection
Any loss of vision
Have you suffered a permanent loss or change in vision?
I have suffered a permanent change or loss in my vision
My vision is the same as before my infection
Are you still able to wear contact lenses?
I am able to wear contact lenses
I can no longer wear contact lenses
Date of injury:
How long did you have to treat for your eye infection?
Did you miss any work?
How long did you use medications?
Were you using ReNu with MoistureLoc in the month prior to your eye infection? Yes No
I have been treated with:
Antifungal eye drops
Antifungal ointment
Oral Antibiotic
Antifungal injection
Steroid eye drops
Eye Surgery
Corneal scraping
Corneal biopsy
Corneal debridement
Ultrasound of eye
Have you had a corneal transplant? Yes No
If yes, please enter date:
Have you been given medications for your eye infection? Yes No
Have you been told by a Doctor that you may need a corneal transplant? Yes No
If yes to any of the above, please describe:
Additional Comments/Questions
Philadelphia Lawyers - Pennsylvania Lawsuits at Monheit Law

Law Offices of Michael Monheit 1368 Barrowdale Road  Rydal, PA  19046
Call Us Toll Free: 866-761-1385  P: 215-840-6573  E: Michael@Monheit.com